DYNC2I2: A Protein Target for Neurodegenerative Diseases (G89891)

Target Name: DYNC2I2

NCBI ID: G89891

DYNC2I2

DYNC2I2: A Protein Target for Neurodegenerative Diseases

DYNC2I2 (SRTD11) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of the development and maintenance of the myocardium, which is the heart muscle. Mutations in the DYNC2I2 gene have been linked to a range of cardiovascular and neurological disorders, including heart failure, sudden infant death syndrome (SIDS), and neurodegenerative diseases.

In addition to its role in the myocardium, DYNC2I2 is also involved in the regulation of the blood-brain barrier (BBB), which is a specialized barrier that separates the brain from the blood and helps to protect it from harmful substances. DYNC2I2 is thought to play a key role in the development of neurocancer, as well as in the regulation of neurotransmitter release and synaptic plasticity.

DYNC2I2 is a protein that is expressed in the brain, heart, and kidneys. It is a key regulator of the development and maintenance of the myocardium, as well as the blood-brain barrier. DYNC2I2 mutations have been linked to a range of cardiovascular and neurological disorders.

One of the most promising aspects of DYNC2I2 is its potential as a drug target. Researchers have identified several potential drug targets for DYNC2I2, including those that are involved in the regulation of ion channels, neurotransmitter release, and cell signaling pathways. These targets may be useful for the development of new treatments for a range of neurodegenerative diseases, including heart failure, SIDS, and neurocancer.

In addition to its potential as a drug target, DYNC2I2 is also an attractive biomarker for the diagnosis and prognosis of neurodegenerative diseases. The DYNC2I2 gene has been mutated in a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Researchers have used these mutations to develop diagnostic tests for these diseases, as well as to track the progression of disease and the effectiveness of new treatments.

Overall, DYNC2I2 is a protein that has the potential to be a drug target and a biomarker for a range of neurodegenerative diseases. Further research is needed to fully understand its role and to develop new treatments based on its properties.

Protein Name: Dynein 2 Intermediate Chain 2

Functions: Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 2 complex (dynein-2 complex), a motor protein complex that drives the movement of cargos along microtubules within cilia and flagella in concert with the intraflagellar transport (IFT) system (PubMed:25205765, PubMed:29742051). DYNC2I2 plays a major role in retrograde ciliary protein trafficking and in ciliogenesis (PubMed:30649997, PubMed:29742051, PubMed:30320547). Required also to maintain a functional transition zone (PubMed:30320547)

The "DYNC2I2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DYNC2I2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets